ASH 2024: AstraZeneca set to take a BiTE out of follicular lymphoma market
GlobalData’s analysts predict $158 million in global sales for AZD0486 by 2030, with $2.4 billion for Epkinly and $949 ...
pharmaphorum7 个月
Amgen adds BiTE to its cancer range as FDA clears Imdelltra
BiTE drugs are designed to engage the immune system against cancer by bringing T-cells and cancer cells into close proximity. In the case of tarlatamab, the molecule binds to CD3 receptors on T ...
pharmaphorum1 天
FDA starts speedy review of Amgen’s lung cancer BiTE therapy
BiTE drugs are designed to engage the immune system against cancer by the expedient of bringing T cells and cancer cells into close proximity. In the case of tarlatamab, the molecule binds to CD3 ...